Sun, pivoting to specialty pharma, wins psoriasis nod for Ilumya. Can it hang with J&J?

FDA
The FDA approved Sun's Ilumya Wednesday. (Image: FDA)

Sun Pharma’s $80 million psoriasis licensing deal with Merck & Co. just paid off with an FDA approval. But now, another challenge begins: The new med will go up against established psoriasis player Johnson & Johnson.

The FDA has officially green-lighted the Indian drugmaker’s Ilumya, an IL-23 inhibitor, to treat the skin plaque disease, Sun said Wednesday. It’s “sort of a flagship product” for the company, which has only recently pivoted its focus to spec pharma after many years on the generics scene, Chief Medical Officer Simon Lowry said in an interview.

RELATED: Sun noses ahead of J&J in race for IL-23 finish line, but other rivals lie in wait

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

While pharma-watchers once believed Ilumya just might make it to market before head-to-head rival Tremfya from J&J, the New Jersey pharma giant ultimately usurped that lead and snagged its FDA go-ahead last July. And now it will be up to Sun to distinguish its newcomer with doctors.

The way Lowry sees it, that won’t be difficult. Ilumya bears a less-frequent dosing schedule, requiring doses just every 12 weeks after two initial treatments, one to start and another at Week 4. Tremfya, on the other hand, is taken every eight weeks after the starter doses.

“We think that that will fit quite nicely with the natural flow of the dermatology office; bring the patient back every 12 weeks to see how they’re doing and administer the next dose,” Lowry said.

While less-frequent dosing may be more convenient for patients, Tremfya also has an at-home dosing option that could offer its own convenience edge. But that option also poses adherence uncertainties, Lowry pointed out.

RELATED: Lilly chases third Taltz-Cosentyx matchup with new ankylosing spondylitis data

“We’ve spoken to a lot of physicians who say they like the ability to bring the patient back in every 12 weeks and make sure they get their dose. When the patients are home, you aren’t sure whether they’re actually administering the drug or not,” he said.

J&J has an additional advantage, too, in its relationships with docs. The company also markets blockbuster Stelara, an IL-12/IL-23 drug that’s been around for years. And while Ilumya isn’t Sun’s first branded dermatology product, comparatively speaking, it’s still early days for the company in the field.

Meanwhile, Tremfya is far from the only psoriasis newcomer that Ilumya will have to fight. The IL-17 field has seen a burst of recent activity from Novartis’ Cosentyx, Eli Lilly’s Taltz and Valeant’s Siliq. And Novartis and Taltz have already expanded into areas such as psoriatic arthritis and ankylosing spondylitis, indications that Sun is developing Ilumya for as well.